Caribou Biosciences initiates lupus trial, plans 2025 data milestones, hires new CFO

Caribou Biosciences, Inc.

Initiated GALLOP Phase 1 trial of CB-010 in lupus nephritis and extrarenal lupus; FDA Fast Track for refractory SLE.
CB-010 ANTLER and CB-011 CaMMouflage Phase 1 data expected H1 2025; CB-010 pivotal Phase 3 planned H2 2025 pending HLA matching.
CB-012 AMpLify Phase 1 in r/r AML: dose level 3 completed with no DLTs; enrolling dose level 4.
Sri Ryali appointed CFO; $281M cash expected to fund operations into H2 2026.
CB-012 granted FDA Fast Track and Orphan Drug designation for r/r AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.